JTCS Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Robert James Cerfolio
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cerfolio, R. J.
Right arrow Articles by Katholi, C. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cerfolio, R. J.
Right arrow Articles by Katholi, C. R.
Related Collections
Right arrow Lung - cancer

J Thorac Cardiovasc Surg 2003;125:938-944
© 2003 The American Association for Thoracic Surgery


General Thoracic Surgery

Positron emission tomography scanning with 2-fluoro-2-deoxy-D-glucose as a predictor of response of neoadjuvant treatment for non-small cell carcinoma

Robert James Cerfolio, MD, FACS, FCCPa, Buddhiwardhan Ojha, MD, MPHb, Sudipto Mukherjee, MDb, Amanda Harrison Pask, RN, BSNa, Cynthia Sale Bass, RN, MSN, CRNPa, Charles R. Katholi, PhDc

From the Department of Cardio-Thoracic Surgery,a the Department of Radiology, Division of Nuclear Medicine,b and the Department of Biostatistics,c University of Alabama at Birmingham, Ala.

Read at the Twenty-eighth Annual Meeting of The Western Thoracic Surgical Association, Big Sky, Mont, June 19-22, 2002.

Received for publication July 10, 2002. Revisions requested Aug 19, 2002; revisions received Oct 7, 2002. Accepted for publication Oct 18, 2002. Address for reprints: Robert J. Cerfolio, MD, Associate Professor of Surgery, Division of Cardiothoracic Surgery, University of Alabama at Birmingham, 1900 University Blvd, THT 712, Birmingham, AL 35294 (E-mail: Robert.cerfolio{at}ccc.uab.edu).

Objectives: Surgical resection after preoperative chemotherapy in patients with non-small cell lung cancer might only be best for patients who are responders. We compared positron emission tomographic scanning with 2-fluoro-2-deoxy-D-glucose (FDP-PET scanning) with computed tomographic scanning to evaluate their ability to predict this response for the primary tumor, N1 and N2 lymph nodes.
Methods: All patients with non-small cell lung cancer who had an initial FDP-PET scan staging with tissue biopsy, neoadjuvant chemotherapy, repeat FDP-PET scanning, and repeat biopsies were prospectively studied.
Results: There were 34 patients (24 men; median age, 64 years). Eleven patients had N2 disease, and 7 had N1 disease. Twenty-seven patients received chemotherapy, and 7 patients received chemotherapy and radiation. All but 9 patients underwent resection. Statistical analysis showed FDP-PET scanning to be more specific (P < .0001), to have a higher positive predictive value (P = .0018), and to have a higher negative predictive value (P < .0001) than computed tomographic scanning for predicting residual tumor at the primary site. FDP-PET scanning was more sensitive (P < .0001) and more accurate (P < .0001), had a higher positive predictive value (P < .0001), and had a higher negative predictive value (P = .0002) than computed tomographic scanning for paratracheal nodes (number 2 and 4 lymph nodes). FDP-PET scanning had a higher positive predictive value (P < .0001) than computed tomographic scanning for the other N2 (numbers 5, 6, 7, 8, and 9) lymph nodes.
Conclusions: Repeat FDP-PET scanning is more specific and has a higher positive predictive value and negative predictive value than computed tomographic scanning for detecting residual tumor in the lung in patients with non-small cell lung cancer who have received preoperative chemotherapy. It is more sensitive and accurate for paratracheal N2 nodes as well. However, there is no significant difference in its detection of N1 lymph nodes.




This article has been cited by other articles:


Home page
JCOHome page
F. J.F. Herth, J. T. Annema, R. Eberhardt, K. Yasufuku, A. Ernst, M. Krasnik, and R. C. Rintoul
Endobronchial Ultrasound With Transbronchial Needle Aspiration for Restaging the Mediastinum in Lung Cancer
J. Clin. Oncol., July 10, 2008; 26(20): 3346 - 3350.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
R. J. Cerfolio and A. S. Bryant
When is it Best to Repeat a 2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography Scan on Patients with Non-Small Cell Lung Cancer Who Have Received Neoadjuvant Chemoradiotherapy?
Ann. Thorac. Surg., October 1, 2007; 84(4): 1092 - 1097.
[Abstract] [Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
P. De Leyn, D. Lardinois, P. E. Van Schil, R. Rami-Porta, B. Passlick, M. Zielinski, D. A. Waller, T. Lerut, and W. Weder
ESTS guidelines for preoperative lymph node staging for non-small cell lung cancer
Eur. J. Cardiothorac. Surg., July 1, 2007; 32(1): 1 - 8.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
P. De Leyn, S. Stroobants, W. De Wever, T. Lerut, W. Coosemans, G. Decker, P. Nafteux, D. Van Raemdonck, L. Mortelmans, K. Nackaerts, et al.
Prospective Comparative Study of Integrated Positron Emission Tomography-Computed Tomography Scan Compared With Remediastinoscopy in the Assessment of Residual Mediastinal Lymph Node Disease After Induction Chemotherapy for Mediastinoscopy-Proven Stage IIIA-N2 Non-Small-Cell Lung Cancer: A Leuven Lung Cancer Group Study
J. Clin. Oncol., July 20, 2006; 24(21): 3333 - 3339.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
R. J. Cerfolio, A. S. Bryant, and B. Ojha
Restaging patients with N2 (stage IIIa) non-small cell lung cancer after neoadjuvant chemoradiotherapy: A prospective study
J. Thorac. Cardiovasc. Surg., June 1, 2006; 131(6): 1229 - 1235.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Roentgenol.Home page
O. Mawlawi, J. J. Erasmus, T. Pan, D. D. Cody, R. Campbell, A. H. Lonn, S. Kohlmyer, H. A. Macapinlac, and D. A. Podoloff
Truncation Artifact on PET/CT: Impact on Measurements of Activity Concentration and Assessment of a Correction Algorithm.
Am. J. Roentgenol., May 1, 2006; 186(5): 1458 - 1467.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
T. Bunyaviroch and R. E. Coleman
PET Evaluation of Lung Cancer
J. Nucl. Med., March 1, 2006; 47(3): 451 - 469.
[Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
C. Pottgen, S. Levegrun, D. Theegarten, S. Marnitz, S. Grehl, R. Pink, W. Eberhardt, G. Stamatis, T. Gauler, G. Antoch, et al.
Value of 18F-Fluoro-2-Deoxy-D-Glucose-Positron Emission Tomography/Computed Tomography in Non-Small-Cell Lung Cancer for Prediction of Pathologic Response and Times to Relapse after Neoadjuvant Chemoradiotherapy
Clin. Cancer Res., January 1, 2006; 12(1): 97 - 106.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
C. J. Hoekstra, S. G. Stroobants, E. F. Smit, J. Vansteenkiste, H. van Tinteren, P. E. Postmus, R. P. Golding, B. Biesma, F. J.H.M. Schramel, N. van Zandwijk, et al.
Prognostic Relevance of Response Evaluation Using [18F]-2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography in Patients With Locally Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol., November 20, 2005; 23(33): 8362 - 8370.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
B. Milleron, V. Westeel, E. Quoix, D. Moro-Sibilot, D. Braun, B. Lebeau, A. Depierre, and for the French Thoracic Cooperative Group
Complete Response Following Preoperative Chemotherapy for Resectable Non-Small Cell Lung Cancer: Accuracy of Clinical Assessment Using the French Trial Database
Chest, September 1, 2005; 128(3): 1442 - 1447.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
L. K. Shankar and D. C. Sullivan
Functional Imaging in Lung Cancer
J. Clin. Oncol., May 10, 2005; 23(14): 3203 - 3211.
[Abstract] [Full Text] [PDF]


Home page
Jpn J Clin OncolHome page
T. Ohtsuka, H. Nomori, K. Watanabe, T. Naruke, H. Orikasa, K. Yamazaki, K. Suemasu, and K. Uno
False-positive Findings on [18F]FDG-PET Caused by Non-neoplastic Cellular Elements After Neoadjuvant Chemoradiotherapy for Non-small Cell Lung Cancer
Jpn. J. Clin. Oncol., May 1, 2005; 35(5): 271 - 273.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
O. Birim, A. P. Kappetein, T. Stijnen, and A. J.J.C. Bogers
Meta-Analysis of Positron Emission Tomographic and Computed Tomographic Imaging in Detecting Mediastinal Lymph Node Metastases in Nonsmall Cell Lung Cancer
Ann. Thorac. Surg., January 1, 2005; 79(1): 375 - 382.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
D. Hellwig, T. P. Graeter, D. Ukena, T. Georg, C.-M. Kirsch, and H.-J. Schafers
Value of F-18-fluorodeoxyglucose positron emission tomography after induction therapy of locally advanced bronchogenic carcinoma
J. Thorac. Cardiovasc. Surg., December 1, 2004; 128(6): 892 - 899.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
R. J. Cerfolio, A. S. Bryant, T. S. Winokur, B. Ohja, and A. A. Bartolucci
Repeat FDG-PET After Neoadjuvant Therapy is a Predictor of Pathologic Response in Patients With Non-Small Cell Lung Cancer
Ann. Thorac. Surg., December 1, 2004; 78(6): 1903 - 1909.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
F. C. Detterbeck, J. F. Vansteenkiste, D. E. Morris, C. A. Dooms, A. H. Khandani, and M. A. Socinski
Seeking a Home for a PET, Part 3: Emerging Applications of Positron Emission Tomography Imaging in the Management of Patients With Lung Cancer
Chest, November 1, 2004; 126(5): 1656 - 1666.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. De Santis, A. Becherer, C. Bokemeyer, F. Stoiber, K. Oechsle, F. Sellner, A. Lang, K. Kletter, B. M. Dohmen, C. Dittrich, et al.
2-18fluoro-deoxy-D-glucose Positron Emission Tomography Is a Reliable Predictor for Viable Tumor in Postchemotherapy Seminoma: An Update of the Prospective Multicentric SEMPET Trial
J. Clin. Oncol., March 15, 2004; 22(6): 1034 - 1039.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
R. J. Cerfolio, B. Ojha, A. S. Bryant, C. S. Bass, A. A. Bartalucci, and J. M. Mountz
The role of FDG-PET scan in staging patients with nonsmall cell carcinoma
Ann. Thorac. Surg., September 1, 2003; 76(3): 861 - 866.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2003 by The American Association for Thoracic Surgery.